AG
RCKT icon

Algert Global’s Rocket Pharmaceuticals RCKT Stock Holding History

Algert Global’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-341,760
Closed -$837K – 1305
2025
Q2 		$837K Buy
341,760
+286,250
+516% +$1.45M 0.02% 843
2025
Q1 		$370K Buy
55,510
+15,450
+39% +$153K 0.01% 970
2024
Q4 		$504K Buy
+40,060
New +$603K 0.01% 905
2024
Q1 		– Sell
-24,710
Closed -$741K – 1236
2023
Q4 		$741K Buy
+24,710
New +$545K 0.03% 698
2023
Q1 		– Sell
-49,768
Closed -$974K – 1278
2022
Q4 		$974K Sell
49,768
-1,760
-3% -$32.4K 0.05% 580
2022
Q3 		$822K Buy
51,528
+10,758
+26% +$168K 0.05% 619
2022
Q2 		$561K Buy
40,770
+18,460
+83% +$220K 0.04% 718
2022
Q1 		$354K Buy
+22,310
New +$385K 0.02% 925
2021
Q1 		– Sell
-9,294
Closed -$510K – 511
2020
Q4 		$510K Sell
9,294
-13,127
-59% -$479K 0.15% 222
2020
Q3 		$513K Hold
22,421
– – 0.16% 189
2020
Q2 		$469K Sell
22,421
-5,409
-19% -$97.5K 0.16% 198
2020
Q1 		$388K Buy
+27,830
New +$551K 0.16% 205

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Algert Global's RCKT Position: Q3 2025 in Review

Algert Global sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 341,760 shares — an estimated $837K sold.

Algert Global first reported a position in RCKT in Q1 2020 and held it in 12 quarters. The position peaked at $974K in Q4 2022. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Algert Global reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 341,760 Rocket Pharmaceuticals shares in Q3 2025, an estimated $837K.
  • Algert Global first reported a position in Rocket Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • Algert Global's Rocket Pharmaceuticals position peaked at $974K in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.